|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
As a response to a published report documenting some expression of folate receptor alpha in human mesothelioma, studies were carried out examining the role of this receptor versus that of the reduced folate carrier in the internalization of folate analogs in this neoplasm.
|
12019370 |
2002 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Epidemiologic and clinical studies using human tumor specimens are lacking and increasingly needed to understand the role of environmental and genetic influences on FOLR1 expression in tumor etiology and progression.
|
16453285 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We report that CART cells targeting the folate receptor alpha (FR-α) successfully infiltrated preestablished xenograft tumors but failed to induce complete responses, presumably due to the presence of antigen-negative cancer cells.
|
29588319 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DATA CONCLUSION: <sup>19</sup> F MRI with FR-targeted PFC nanoparticles can be used in differentiating of FR-positive and FR-negative tumors, and further, in evaluation of the two cancer models proliferation.
|
29756310 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Eligibility included a minimum requirement of tumor FRα positivity (≥25% of cells with ≥2+ staining intensity).
|
30093227 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The correlation between <sup>89</sup>Zr-M9346A tumor uptake and treatment response using IMGN853 in FRα<sup>high</sup> TNBC PDX model suggested the potential of <sup>89</sup>Zr-M9346A PET as a noninvasive tool to prescreen patients based on the in vivo PET imaging for IMGN853-targeted treatment.
|
31369274 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that PyMT-induced breast tumours highly express the cancer-specific folate receptor (FR), a feature they share with several human epithelial cancers in which expression of FRα correlates with tumour grade.
|
28152548 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In our previous study, we demonstrated that folate-appended methyl‑β‑cyclodextrin (FA-M-β-CyD) was a promising antitumor agent for the treatment of folate receptor-α (FR-α)-expressing tumors.
|
29486262 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
FOLR1 expression did not correlate to common clinicopathological parameters such as tumor stage and nodal status.
|
25816016 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Growth analysis revealed that FBP-transfected NIH/3T3 cells like IGROV1 maintained their growth rate after 10 days of culture in medium containing physiological or low folate concentration, and tumors arising after transplanting FBP-tNIH/3T3 cells in nude mice were 3-fold heavier than those arising after transplantation of non-FBP-expressing NIH/3T3 cells.
|
8242637 |
1993 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Concordance of FRα expression in biopsy versus archival tumor samples suggests that archival tissue can reliably identify patients with receptor-positive tumors and is appropriate for patient selection in mirvetuximab soravtansine clinical trials.
|
28843653 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), IMGN853, shows great antitumor activity against FRα-expressing tumors in vivo, but patient selection and consequently therapy outcome are based on immunohistochemistry.
|
30155674 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our work has demonstrated that localized delivery of FR-targeted PAMAM dendrimer G4 complexed with siVEGFA resulted in pronounced tumor suppression in an HN12 xenograft tumor model.
|
28438704 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although in primary EOC specimens, FRα is widely expressed and increases with tumor stage, PCFT was expressed independent of tumor stage (by real-time RT-PCR and IHC).
|
28138029 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Target genes in these regions are termed 'forerunner genes' (FR genes), based on the concept that these genes enable the initial clonal expansion of in situ urothelial neoplasia.
|
18475256 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Developing blastula and tumor cells both require folr1 expression to obtain folate.
|
28826993 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Regarding biodistribution, intravenous (I.V.) administration showed a slight advantage of FRα targeted over non-targeted micelleplex accumulation within the tumor.
|
29935386 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Consistent with this, FOLR1 expression in tumors progressing following cisplatin treatment was lower than levels in tumors in remission (P < 0.01).
|
29433550 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have demonstrated the effectiveness of FA conjugated QDs to target tumor spheroids thus confirming the crucial role of FRα receptor as a target.
|
30885845 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor targeting with folic acid radioconjugates has been proposed as a promising strategy for radionuclide therapy of folate receptor α (FR)-positive cancer.
|
28094532 |
2017 |